Histone Deacetylase Inhibitors Promote Osteoblast Maturation
- 1 December 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 20 (12), 2254-2263
- https://doi.org/10.1359/jbmr.050813
Abstract
HDIs are potential therapeutic agents for cancer and neurological diseases because of their abilities to alter gene expression, induce growth arrest or apoptosis of tumors cells, and stimulate differentiation. In this report, we show that several HDIs promote osteoblast maturation in vitro and in calvarial organ cultures.Keywords
This publication has 51 references indexed in Scilit:
- Histone Deacetylase 3 Interacts with Runx2 to Repress the Osteocalcin Promoter and Regulate Osteoblast DifferentiationJournal of Biological Chemistry, 2004
- Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone HyperacetylationClinical Cancer Research, 2004
- Histone deacetylase inhibitors – a new tool to treat cancerCancer Treatment Reviews, 2004
- Bone mineral metabolism changes in epileptic children receiving valproic acidJournal of Paediatrics and Child Health, 2004
- The effect of valproate on bone mineral density in adult epileptic patientsPharmacological Research, 2004
- Trichostatin A activates the osteopontin gene promoter through AP1 siteBiochemical and Biophysical Research Communications, 2004
- Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular DifferentiationCancer Research, 2004
- p15INK4b in HDAC inhibitor‐induced growth arrestFEBS Letters, 2003
- Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophagesBlood, 2003
- The Human Histone Deacetylase FamilyExperimental Cell Research, 2001